Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LBP-AIEC01
- Development stage
- Preclinical
- Lead developer
- Locus Biosciences
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Live Biotherapeutic Products → Microbiome Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics
01
Overview
LBP-AIEC01 is an investigational engineered bacteriophage therapy developed by Locus Biosciences for the treatment of inflammatory bowel disease (IBD) and Crohn's disease. It is a precision medicine designed to selectively target and eliminate adherent-invasive E. coli (AIEC), a type of bacteria implicated in the pathogenesis of Crohn's disease. LBP-AIEC01 utilizes CRISPR-Cas3 technology to enhance the phage's natural lytic activity, leading to the destruction of the target bacteria. It is part of the company's pipeline of precision antibacterial therapeutics.
Beyond the preview
Go deeper on LBP-AIEC01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LBP-AIEC01.